Clinical Trial Update: AGN-229666 for the Treatment of Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of AGN-229666 for allergic conjunctivitis completed; results were posted in February 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• AGN-229666

Snippet

Sponsor: Allergan | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2014-02-04